Vigmed publishes prospectus concerning the rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION
WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS
The prospectus concerning Vigmed Holding AB’s (publ) (“Vigmed” or the “Company”)
rights issue has been approved and registered by the Swedish Financial
Supervisory Authority and is available on the Company’s website www.vigmed.com
and on Remium’s website www.remium.com.

Vigmed has engaged ABG Sundal Collier as financial advisors and Mannheimer
Swartling Advokatbyrå as legal advisor in connection with the rights issue.

Vigmed discloses the information in this press release pursuant to the Swedish
Securities Markets Act.

The information was provided for public release on 12 November 2014 at 08:00
CET.
For further information contact:

Chairman of the board, Lennart Holm 46 70 630 8562 or CEO, Finn Ketler 46 42 600
5311, e-mail fk@vigmed.com
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market unique needle-protected products.
Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20
employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm
(ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the
Company’s Certified Advisor.

Additional information such as company description, a video presentation and
risk factors can be found on Vigmed’s website: www.vigmed.com/investor